Related references
Note: Only part of the references are listed.American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Projections of the costs associated with colorectal cancer care in the United States, 2000-2020
K. Robin Yabroff et al.
HEALTH ECONOMICS (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Expensive cancer drugs with modest benefit ignite debate over solutions
Gunjan Sinha
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Evaluation of trends in the cost of initial cancer treatment
Joan L. Warren et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment
N. Starling et al.
BRITISH JOURNAL OF CANCER (2007)
A stated preference binary choice experiment to explore NICE decision making
Paul Tappenden et al.
PHARMACOECONOMICS (2007)
Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis
J. Norum
JOURNAL OF CHEMOTHERAPY (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
'Lost in translation' - Accounting for between-country differences in the analysis of multinational cost-effectiveness data
Andrea Manca et al.
PHARMACOECONOMICS (2006)
Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas
K Fransén et al.
CARCINOGENESIS (2004)
Use of cost-effectiveness analysis in health-care resource allocation decision-making:: How are cost-effectiveness thresholds expected to emerge?
HG Eichler et al.
VALUE IN HEALTH (2004)
National Institute for Clinical Excellence and its value judgments
MD Rawlins et al.
BRITISH MEDICAL JOURNAL (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Assessing the appropriateness of combining economic data from multinational clinical trials
JR Cook et al.
STATISTICS IN MEDICINE (2003)
Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma
HJN Andreyev et al.
GUT (2001)
The EGF receptor family as targets for cancer therapy
J Mendelsohn et al.
ONCOGENE (2000)
Willingness to pay for a quality-adjusted life year: In search of a standard
RA Hirth et al.
MEDICAL DECISION MAKING (2000)
Share Paper
